Skip to main navigation Skip to search Skip to main content

Neoadjuvant chemotherapy for breast cancer—background for the indication of locoregional treatment

David Krug, René Baumann, Wilfried Budach, Jürgen Dunst, Petra Feyer, Rainer Fietkau, Wulf Haase, Wolfgang Harms, Thomas Hehr, Marc D. Piroth, Felix Sedlmayer, Rainer Souchon, Frederik Wenz, Rolf Sauer

Abstract

© 2018, Springer-Verlag GmbH Germany, part of Springer Nature. Neoadjuvant chemotherapy (NACT) has been widely adopted into the multidisciplinary management of breast cancer. The prognostic impact of treatment response has been clearly demonstrated. However, the impact of treatment response on the indication for adjuvant radiotherapy is unclear. This review summarizes important implications of NACT and treatment response on the risk of recurrence and locoregional multidisciplinary management from the standpoint of radiation oncology.
Original languageEnglish
JournalStrahlentherapie und Onkologie
Volume194
Issue number9
Pages (from-to)797-805
Number of pages9
ISSN0179-7158
DOIs
Publication statusPublished - 01.09.2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Neoadjuvant chemotherapy for breast cancer—background for the indication of locoregional treatment'. Together they form a unique fingerprint.

Cite this